Premature Infant Clinical Trials

Find Premature Infant Clinical Trials Near You

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 7 days
Healthy Volunteers: f
View:

• Preterm neonates with gestational age ≤ 32 weeks, admitted to the NICU and diagnosed with patent ductus arteriosus by echocardiography on day 3 of life.

Locations
Other Locations
Egypt
Faculty of Medicine, Ain Shams, University
RECRUITING
Cairo
Contact Information
Primary
Mennatallah Ayman ayman, MD student
menahayman@gmail.com
+201004137614
Backup
Sondos Ahmed
menahayman@gmail.com
Time Frame
Start Date: 2026-01
Estimated Completion Date: 2026-04
Participants
Target number of participants: 34
Treatments
group1, hemodynamically significant PDA
fulfilling the following criteria PDA measuring \> 1.5 mm and predominantly left-to-right shunt. LA/Ao ratio between 1.4 and 1.6 in moderate PDA and \>1.6 in large PDA. Left pulmonary artery (LPA) diastolic flow velocity of \>0.25 m/sec. Systemic hypo perfusion: absent or reversed diastolic flow in the Aorta Group1will receive anti-PGE; Ibuprofen (IBU) (brufen)® syrup will be given for 3 days enterally either orally or via a gastric tube with an initial dose of 10mg/kg/day, followed by 5mg/kg/day for the next 2 days
group2, hemodynamically insignificant PDA
Spontaneous closure group by echocardiography
Sponsors
Leads: Ain Shams University

This content was sourced from clinicaltrials.gov